TSRL, Inc. is a privately-owned preclinical accelerator based in Ann Arbor, Michigan. Long time SBIR involved and originally focused on developing oral drug delivery technologies, the firm expanding over time to include prodrug strategies for existing drug products. TSRLs preclinical accelerator model was introduced in 2014 follwing input from collaborators that they were having difficulty finding support for their lead-stage projects. Under this enhaned approach, TSRL helps investigators advance their promising lead candidates to clinical-readiness by providing in-house data-generation capabilities, process management oversight, and business development expertise. Their team of industry veterans has broad experience in molecular biology, biochemistry, analytical chemistry, in vivo animal models, PK/ADME, toxicology, and formulation. A strategic priority for TSRL is developing treatments for multi-drug resistant infectious diseases, including antivirals and antibacterials. Preclinical development is complicated, costly, and time-consuming. Many therapeutic assets are struggling to find funding to move past the Valley of Death, where substantial investment in in vitro and in vivo studies is necessary to produce the compelling data required to reach the next inflection point. TSRLs preclinical accelerator is designed to give investigators access to a growing number of non-dilutive funding opportunities. The company offers internal scientific and business support, including access to our network of collaborators and consultants, and provides an industry perspective on study design with project management oversight to generate data necessary to be competitive for these grant opportunities. Given that the anti-infectives field is continuing to experience a resurgence in activity due to the increasing threat of antimicrobial resistance. In addition to increased federal support to address thisproblem, greater interest from clinical sponsors and investment groups, resulting in historical highs of capital investment. Moreover, venture funding of US therapeutic companies is trending toward earlier stage programs. TSRL and its partners combine their relative strengths and develop new drugs that take advantage of the funding climate, ultimately giving providers new weapons in the war against drug-resistant pathogens.
